Dabrafenib and Trametinib for Non-Small Cell Lung Cancer BRAF V600 Mutation - Details


( Last Updated : May 28, 2021)
Generic Name:
Dabrafenib and Trametinib
Project Status:
Complete
Therapeutic Area:
NSCLC BRAF V600
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Brand Name:
Tafinlar and Mekinist
Project Line:
Reimbursement Review
Project Number:
PC0226-000
NOC Date:

Details


Tumour Type:
Lung
Indications:
Non-Small Cell Lung Cancer (NSCLC) BRAF V600 mutation
Funding Request:
For the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600 mutation and who have not received any prior anti-cancer therapy for metastatic disease.
Review Status:
Final Recommendation Posted
Sponsor:
Novartis Pharmaceuticals Canada Inc.
Submission Date:
Submission Deemed Complete:
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Final Recommendation Issued (target date):
Funding Request:
For the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600 mutation and who have not received any prior anti-cancer therapy for metastatic disease.
pERC Meeting: